vs

Side-by-side financial comparison of Performance Shipping Inc. (PSHG) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

Performance Shipping Inc. is the larger business by last-quarter revenue ($39.5M vs $35.5M, roughly 1.1× RECURSION PHARMACEUTICALS, INC.). Performance Shipping Inc. runs the higher net margin — 97.5% vs -304.2%, a 401.8% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs -7.9%).

Azerbaijan Caspian Shipping Closed Joint-Stock Company is a state-owned Azerbaijani shipping company. It is also known by its Russian-derived abbreviation CASPAR.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

PSHG vs RXRX — Head-to-Head

Bigger by revenue
PSHG
PSHG
1.1× larger
PSHG
$39.5M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+689.7% gap
RXRX
681.7%
-7.9%
PSHG
Higher net margin
PSHG
PSHG
401.8% more per $
PSHG
97.5%
-304.2%
RXRX

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
PSHG
PSHG
RXRX
RXRX
Revenue
$39.5M
$35.5M
Net Profit
$38.5M
$-108.1M
Gross Margin
59.8%
Operating Margin
93.3%
-304.8%
Net Margin
97.5%
-304.2%
Revenue YoY
-7.9%
681.7%
Net Profit YoY
78.1%
39.6%
EPS (diluted)
$1.00
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PSHG
PSHG
RXRX
RXRX
Q4 25
$35.5M
Q3 25
$5.2M
Q2 25
$39.5M
$19.2M
Q1 25
$14.7M
Q4 24
$4.5M
Q3 24
$26.1M
Q2 24
$42.9M
$14.4M
Q1 24
$13.8M
Net Profit
PSHG
PSHG
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$-162.3M
Q2 25
$38.5M
$-171.9M
Q1 25
$-202.5M
Q4 24
$-178.9M
Q3 24
$-95.8M
Q2 24
$21.6M
$-97.5M
Q1 24
$-91.4M
Gross Margin
PSHG
PSHG
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
PSHG
PSHG
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-3327.6%
Q2 25
93.3%
-916.8%
Q1 25
-1297.9%
Q4 24
-4042.4%
Q3 24
-377.1%
Q2 24
49.1%
-697.4%
Q1 24
-698.4%
Net Margin
PSHG
PSHG
RXRX
RXRX
Q4 25
-304.2%
Q3 25
-3135.3%
Q2 25
97.5%
-894.2%
Q1 25
-1373.3%
Q4 24
-3935.5%
Q3 24
-367.5%
Q2 24
50.4%
-676.6%
Q1 24
-662.4%
EPS (diluted)
PSHG
PSHG
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$-0.36
Q2 25
$1.00
$-0.41
Q1 25
$-0.50
Q4 24
$-0.56
Q3 24
$-0.34
Q2 24
$0.55
$-0.40
Q1 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PSHG
PSHG
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$95.8M
$743.3M
Total DebtLower is stronger
$43.7M
$9.6M
Stockholders' EquityBook value
$312.8M
$1.1B
Total Assets
$363.8M
$1.5B
Debt / EquityLower = less leverage
0.14×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PSHG
PSHG
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$95.8M
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$61.7M
$474.3M
Q1 24
$296.3M
Total Debt
PSHG
PSHG
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$43.7M
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$51.2M
$22.9M
Q1 24
Stockholders' Equity
PSHG
PSHG
RXRX
RXRX
Q4 25
$1.1B
Q3 25
$1.0B
Q2 25
$312.8M
$919.1M
Q1 25
$933.9M
Q4 24
$1.0B
Q3 24
$524.6M
Q2 24
$254.0M
$584.4M
Q1 24
$401.2M
Total Assets
PSHG
PSHG
RXRX
RXRX
Q4 25
$1.5B
Q3 25
$1.4B
Q2 25
$363.8M
$1.3B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$726.5M
Q2 24
$310.5M
$775.9M
Q1 24
$557.8M
Debt / Equity
PSHG
PSHG
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.14×
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.20×
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PSHG
PSHG
RXRX
RXRX
Operating Cash FlowLast quarter
$26.8M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
0.70×
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PSHG
PSHG
RXRX
RXRX
Q4 25
$-46.1M
Q3 25
$-117.4M
Q2 25
$26.8M
$-76.4M
Q1 25
$-132.0M
Q4 24
$-115.4M
Q3 24
$-59.2M
Q2 24
$31.7M
$-82.2M
Q1 24
$-102.3M
Free Cash Flow
PSHG
PSHG
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
PSHG
PSHG
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
PSHG
PSHG
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
0.0%
8.2%
Q1 24
48.2%
Cash Conversion
PSHG
PSHG
RXRX
RXRX
Q4 25
Q3 25
Q2 25
0.70×
Q1 25
Q4 24
Q3 24
Q2 24
1.47×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons